rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-135-144rsp-3542Research ArticleПЕРЕДОВАЯLEADING ARTICLEАгонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологииGlucagon-like peptide-1 receptor agonists: Prospects for use in rheumatologyhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovЕ. L.

Насонов Евгений Львович

115522,  Москва, Каширское шоссе, 34а

Evgeny Nasonov

115522, Moscow, Kashirskoye Highway, 34A

nasonov@irramn.ruhttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinТ. S.

115522, Москва, Каширское шоссе, 34а;

680000, Хабаровск, ул. МуравьеваАмурского, 35

Taras S. Panevin

115522, Moscow, Kashirskoye Highway, 34A;

680000, Khabarovsk, MuravyovaAmurskogo str., 35

https://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaЕ. А.

117036, Москва, ул. Дмитрия Ульянова, 11

Ekaterina A. Troshina

117036, Moscow, Dmitriya Ulyanova str., 11

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Far Eastern State Medical UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияEndocrinology Research CenterRussian Federation202428042024622135144Copyright © Насонов Е.Л., Паневин Т.С., Трошина Е.А., 20242024Насонов Е.Л., Паневин Т.С., Трошина Е.А.Nasonov Е.L., Panevin Т.S., Troshina Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3542

Агонисты рецепторов глюкагоноподобного пептида-1 (АрГПП-1 ) являются эффективными препаратами для лечения сахарного диабета 2-го типа и ожирения. Результаты недавних исследований у пациентов с широким кругом иммуновоспалительных заболеваний свидетельствуют о важных плейотропных механизмах действия этих препаратов, в первую очередь связанных с подавлением воспаления. В статье представлены новые данные, свидетельствующие о перспективах применения АрГПП-1 при иммуновоспалительных ревматических заболеваниях, что диктует необходимость проведения клинических исследований.

Glucagon-like peptide-1 receptor agonists (ArGLP-1) are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immunoinflammatory diseases suggest important pleiotropic mechanisms of action of these drugs, primarily related to the suppression of inflammation. The article presents new data indicating the prospects for the use of ArGLP-1 in immunoinflammatory rheumatic diseases, which dictates the need for clinical studies. GLP-1 receptor agonists are effective drugs for the treatment of type 2 diabetes mellitus and obesity. Recent studies in patients with a wide range of immune-mediated diseases suggest important pleiotropic mechanisms of action of these drugs, primarily related to the suppression of inflammation. The article presents new data indicating the prospects for the use of ArGLP-1 in immune-mediated rheumatic diseases, which dictates the need for clinical studies.

ожирениеиммуновоспалительные ревматические заболеванияэксенатидлираглутидсемаглутиддулаглутидobesityimmune-mediated rheumatic diseasesexenatideliraglutidesemaglutidedulaglutideReferencesWorld Health Organization. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation. World Health Organization; 2000.World Health Organization. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation. World Health Organization; 2000.Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656-1662. doi: 10.2105/AJPH.2016.303326.7Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656-1662. doi: 10.2105/AJPH.2016.303326.7Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World obesity atlas. 2023. URL: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World obesity atlas. 2023. URL: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810-823. doi: 10.1093/ije/dyz273Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810-823. doi: 10.1093/ije/dyz273Mogilenko DA, Sergushichev A, Artyomov MN. Systems immunology approaches to metabolism. Annu Rev Immunol. 2023;41:317-342. doi: 10.1146/annurev-immunol-101220-031513Mogilenko DA, Sergushichev A, Artyomov MN. Systems immunology approaches to metabolism. Annu Rev Immunol. 2023;41:317-342. doi: 10.1146/annurev-immunol-101220-031513Schleh MW, Caslin HL, Garcia JN, Mashayekhi M, Srivastava G, Bradley AB, et al. Metaflammation in obesity and its therapeutic targeting. Sci Transl Med. 2023;15(723):eadf9382. doi: 10.1126/scitranslmed.adf9382Schleh MW, Caslin HL, Garcia JN, Mashayekhi M, Srivastava G, Bradley AB, et al. Metaflammation in obesity and its therapeutic targeting. Sci Transl Med. 2023;15(723):eadf9382. doi: 10.1126/scitranslmed.adf9382Lim Y, Boster J. Obesity and comorbid conditions. Treasure Island (FL):StatPearls Publishing;2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK574535Lim Y, Boster J. Obesity and comorbid conditions. Treasure Island (FL):StatPearls Publishing;2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK574535Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: Common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis. 2018;10(8):157-167. doi: 10.1177/1759720X18783894Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: Common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis. 2018;10(8):157-167. doi: 10.1177/1759720X18783894Shumnalieva R, Kotov G, Ermencheva P, Monov S. Pathogenic mechanisms and therapeutic approaches in obesity-related knee osteoarthritis. Biomedicines. 2023;12(1):9. doi: 10.3390/biomedicines12010009Shumnalieva R, Kotov G, Ermencheva P, Monov S. Pathogenic mechanisms and therapeutic approaches in obesity-related knee osteoarthritis. Biomedicines. 2023;12(1):9. doi: 10.3390/biomedicines12010009Wijesinghe SN, Badoume A, Nanus DE, Sharma-Oates A, Farah H, Certo M, et al. Obesity defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets. Clin Transl Med. 2023;13(4):e1232. doi: 10.1002/ctm2.1232Wijesinghe SN, Badoume A, Nanus DE, Sharma-Oates A, Farah H, Certo M, et al. Obesity defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets. Clin Transl Med. 2023;13(4):e1232. doi: 10.1002/ctm2.1232Li X, Zhu J, Zhao W, Zhu Y, Zhu L, Shi R, et al. The causal effect of obesity on the risk of 15 autoimmune diseases: A Mendelian randomization study. Obes Facts. 2023;16(6):598-605. doi: 10.1159/000534468Li X, Zhu J, Zhao W, Zhu Y, Zhu L, Shi R, et al. The causal effect of obesity on the risk of 15 autoimmune diseases: A Mendelian randomization study. Obes Facts. 2023;16(6):598-605. doi: 10.1159/000534468Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014;73(11):2029-2033. doi: 10.1136/annrheumdis-2013-205094Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014;73(11):2029-2033. doi: 10.1136/annrheumdis-2013-205094Hollander NKD, Boeren AMP, van der Helm-van Mil AHM, van Steenbergen HW. Patients with obesity have more inflamed joints and higher CRP levels during the disease course in ACPApositive RA but not in ACPA-negative RA. Arthritis Res Ther. 2024;26(1):42. doi: 10.1186/s13075-023-03248-8Hollander NKD, Boeren AMP, van der Helm-van Mil AHM, van Steenbergen HW. Patients with obesity have more inflamed joints and higher CRP levels during the disease course in ACPApositive RA but not in ACPA-negative RA. Arthritis Res Ther. 2024;26(1):42. doi: 10.1186/s13075-023-03248-8Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, et al. Overweight, obesity, and the likelihood of achieving sustained remission in early rheumatoid arthritis: Results from a multicenter prospective cohort study. Arthritis Care Res (Hoboken). 2018;70(8):1185-1191. doi: 10.1002/acr.23457Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, et al. Overweight, obesity, and the likelihood of achieving sustained remission in early rheumatoid arthritis: Results from a multicenter prospective cohort study. Arthritis Care Res (Hoboken). 2018;70(8):1185-1191. doi: 10.1002/acr.23457Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: A systematic review and meta-analysis. Arthritis Res Ther. 2016;18(1):297. doi: 10.1186/s13075-016-1194-8Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: A systematic review and meta-analysis. Arthritis Res Ther. 2016;18(1):297. doi: 10.1186/s13075-016-1194-8Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-817. doi: 10.1136/annrheumdis-2013-204448Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-817. doi: 10.1136/annrheumdis-2013-204448Liew JW, Gianfrancesco MA, Heckbert SR, Gensler LS. Relationship between body mass index, disease activity, and exercise in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2022;74(8):1287-1293. doi: 10.1002/acr.24565Liew JW, Gianfrancesco MA, Heckbert SR, Gensler LS. Relationship between body mass index, disease activity, and exercise in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2022;74(8):1287-1293. doi: 10.1002/acr.24565Liew JW, Huang IJ, Louden DN, Singh N, Gensler LS. Association of body mass index on disease activity in axial spondyloarthritis: Systematic review and meta-analysis. RMD Open. 2020;6(1):e001225. doi: 10.1136/rmdopen-2020-001225Liew JW, Huang IJ, Louden DN, Singh N, Gensler LS. Association of body mass index on disease activity in axial spondyloarthritis: Systematic review and meta-analysis. RMD Open. 2020;6(1):e001225. doi: 10.1136/rmdopen-2020-001225Gomez A, Hani Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, et al. Impact of overweight and obesity on patientreported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(3):1260-1272. doi: 10.1093/rheumatology/keaa453Gomez A, Hani Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, et al. Impact of overweight and obesity on patientreported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(3):1260-1272. doi: 10.1093/rheumatology/keaa453Borg A, Lindblom J, Gomez A, Soltani A, Enman Y, Heintz E, et al. Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus. Front Med (Lausanne). 2023;10:1247354. doi: 10.3389/fmed.2023.1247354Borg A, Lindblom J, Gomez A, Soltani A, Enman Y, Heintz E, et al. Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus. Front Med (Lausanne). 2023;10:1247354. doi: 10.3389/fmed.2023.1247354Choi EW, Kim HJ, Jung YC, Go HS, Seong JK. Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus. Sci Rep. 2022;12(1):18532. doi: 10.1038/s41598-022-21381-3Choi EW, Kim HJ, Jung YC, Go HS, Seong JK. Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus. Sci Rep. 2022;12(1):18532. doi: 10.1038/s41598-022-21381-3Nedunchezhiyan U, Varughese I, Sun AR, Wu X, Crawford R, Prasadam I. Obesity, inflammation, and immune system in osteoarthritis. Front Immunol. 2022;13:907750. doi: 10.3389/fimmu.2022.907750Nedunchezhiyan U, Varughese I, Sun AR, Wu X, Crawford R, Prasadam I. Obesity, inflammation, and immune system in osteoarthritis. Front Immunol. 2022;13:907750. doi: 10.3389/fimmu.2022.907750Zhang X, Gao L, Meng H, Zhang A, Liang Y, Lu J. Obesity alters immunopathology in cancers and inflammatory diseases. Obes Rev. 2023;24(12):e13638. doi: 10.1111/obr.13638Zhang X, Gao L, Meng H, Zhang A, Liang Y, Lu J. Obesity alters immunopathology in cancers and inflammatory diseases. Obes Rev. 2023;24(12):e13638. doi: 10.1111/obr.13638Neumann E, Hasseli R, Ohl S, Lange U, Frommer KW, Müller-Ladner U. Adipokines and autoimmunity in inflammatory arthritis. Cells. 2021;10(2):216. doi: 10.3390/cells10020216Neumann E, Hasseli R, Ohl S, Lange U, Frommer KW, MüllerLadner U. Adipokines and autoimmunity in inflammatory arthritis. Cells. 2021;10(2):216. doi: 10.3390/cells10020216Frasca D, Romero M, Diaz A, Blomberg BB. Obesity accelerates age defects in B cells, and weight loss improves B cell function. Immun Ageing. 2023;20(1):35. doi: 10.1186/s12979-023-00361-9Frasca D, Romero M, Diaz A, Blomberg BB. Obesity accelerates age defects in B cells, and weight loss improves B cell function. Immun Ageing. 2023;20(1):35. doi: 10.1186/s12979-023-00361-9Zhang X, Meng J, Shi X, Quinet RJ, Davis W, Zakem J, et al. Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice. Lupus Sci Med. 2023;10(1):e000898. doi: 10.1136/lupus-2023-000898Zhang X, Meng J, Shi X, Quinet RJ, Davis W, Zakem J, et al. Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice. Lupus Sci Med. 2023;10(1):e000898. doi: 10.1136/lupus-2023-000898Matarese G. The link between obesity and autoimmunity. Science. 2023;379(6639):1298-1300. doi: 10.1126/science.ade0113Matarese G. The link between obesity and autoimmunity. Science. 2023;379(6639):1298-1300. doi: 10.1126/science.ade0113Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE. Effect of body mass index on treatment response of biologic/targetedsynthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev. 2023;22(7):103357. doi: 10.1016/j.autrev.2023.103357Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE. Effect of body mass index on treatment response of biologic/targetedsynthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev. 2023;22(7):103357. doi: 10.1016/j.autrev.2023.103357Buch MH, Eyre S, McGonagle D. Persistent inflammatory and noninflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. doi: 10.1038/s41584-020-00541-7Buch MH, Eyre S, McGonagle D. Persistent inflammatory and noninflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. doi: 10.1038/s41584-020-00541-7Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: Current position and considerations for next steps. RMD Open. 2022;8(2):e002387. doi: 10.1136/rmdopen-2022-002387Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: Current position and considerations for next steps. RMD Open. 2022;8(2):e002387. doi: 10.1136/rmdopen-2022-002387Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficultto-treat psoriatic arthritis (D2T PsA): A scoping literature review informing a GRAPPA research project. RMD Open. 2024;10(1):e003809. doi: 10.1136/rmdopen-2023-003809Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficultto-treat psoriatic arthritis (D2T PsA): A scoping literature review informing a GRAPPA research project. RMD Open. 2024;10(1):e003809. doi: 10.1136/rmdopen-2023-003809Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. doi: 10.14412/1995-4484-2018-263-271Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(3):263- 271 (In Russ.)Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: An endocrine society scientific statement. Endocr Rev. 2018;39(2):79-132. doi: 10.1210/er.2017-00253Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: An endocrine society scientific statement. Endocr Rev. 2018;39(2):79-132. doi: 10.1210/er.2017-00253Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther. 2023;251:108549. doi: 10.1016/j.pharmthera.2023.108549Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther. 2023;251:108549. doi: 10.1016/j.pharmthera.2023.108549Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. doi: 10.1136/bmjmed-2022-000372Galindo RJ, Trujillo JM, Low Wang CC, McCoy RG. Advances in the management of type 2 diabetes in adults. BMJ Med. 2023;2(1):e000372. doi: 10.1136/bmjmed-2022-000372Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. doi: 10.1016/j.molmet.2021.101351Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. doi: 10.1016/j.molmet.2021.101351Tomas A, Jones B, Leech C. New insights into beta-cell GLP-1 receptor and cAMP signaling. J Mol Biol. 2020;432(5):1347-1366. doi: 10.1016/j.jmb.2019.08.009Tomas A, Jones B, Leech C. New insights into beta-cell GLP-1 receptor and cAMP signaling. J Mol Biol. 2020;432(5):1347-1366. doi: 10.1016/j.jmb.2019.08.009Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102Mariam Z, Niazi SK. Glucagon-like peptide agonists: A prospective review. Endocrinol Diabetes Metab. 2024;7(1):e462. doi: 10.1002/edm2.462Mariam Z, Niazi SK. Glucagon-like peptide agonists: A prospective review. Endocrinol Diabetes Metab. 2024;7(1):e462. doi: 10.1002/edm2.462Галстян ГР, Каратаева ЕА, Юдович ЕА. Эволюция агонистов рецепторов глюкагоноподобного пептида-1 в терапии сахарного диабета 2 типа. Сахарный диабет. 2017;20(4):286-298. doi: 10.14341/DM8804Galstyan GR, Karataeva EA, Yudovich EA. Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes Mellitus. 2017;20(4):286-298 (In Russ.)Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: 10.3389/fimmu.2023.1148209Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. doi: 10.3389/fimmu.2023.1148209Chen J, Mei A, Wei Y, Li C, Qian H, Min X, et al. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022;13:997578. doi: 10.3389/fimmu.2022.997578Chen J, Mei A, Wei Y, Li C, Qian H, Min X, et al. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022;13:997578. doi: 10.3389/fimmu.2022.997578Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022;182:106320. doi: 10.1016/j.phrs.2022.106320Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022;182:106320. doi: 10.1016/j.phrs.2022.106320Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease. Korean J Intern Med. 2022;37(1):13-26. doi: 10.3904/kjim.2021.363Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease. Korean J Intern Med. 2022;37(1):13-26. doi: 10.3904/kjim.2021.363Nojima I, Wada J. Metformin and its immune-mediated effects in various diseases. Int J Mol Sci. 2023;24(1):755. doi: 10.3390/ijms24010755Nojima I, Wada J. Metformin and its immune-mediated effects in various diseases. Int J Mol Sci. 2023;24(1):755. doi: 10.3390/ijms24010755Salvatore T, Pafundi PC, Galiero R, Gjeloshi K, Masini F, Acierno C, et al. Metformin: A potential therapeutic tool for rheumatologists. Pharmaceuticals (Basel). 2020;13(9):234. doi: 10.3390/ph13090234Salvatore T, Pafundi PC, Galiero R, Gjeloshi K, Masini F, Acierno C, et al. Metformin: A potential therapeutic tool for rheumatologists. Pharmaceuticals (Basel). 2020;13(9):234. doi: 10.3390/ph13090234Bharath LP, Nikolajczyk BS. The intersection of metformin and inflammation. Am J Physiol Cell Physiol. 2021;320(5):C873-C879. doi: 10.1152/ajpcell.00604.2020Bharath LP, Nikolajczyk BS. The intersection of metformin and inflammation. Am J Physiol Cell Physiol. 2021;320(5):C873-C879. doi: 10.1152/ajpcell.00604.2020Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-433. doi: 10.14412/1995-4484-2015-421-433Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(4):421-433. (In Russ.)Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0235637. doi: 10.1371/journal.pone.0235637Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0235637. doi: 10.1371/journal.pone.0235637Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58. doi: 10.1038/nrd.2018.168Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58. doi: 10.1038/nrd.2018.168Qin C, Diaz-Gallo LM, Tang B, Wang Y, Nguyen TD, Harder A, et al. Repurposing antidiabetic drugs for rheumatoid arthritis: Results from a two-sample Mendelian randomization study. Eur J Epidemiol. 2023;38(7):809-819. doi: 10.1007/s10654-023-01000-9Qin C, Diaz-Gallo LM, Tang B, Wang Y, Nguyen TD, Harder A, et al. Repurposing antidiabetic drugs for rheumatoid arthritis: Results from a two-sample Mendelian randomization study. Eur J Epidemiol. 2023;38(7):809-819. doi: 10.1007/s10654-023-01000-9Karpouzas GA, Husni ME. Cardiovascular comorbidities in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2023;49(1):XV-XVI. doi: 10.1016/j.rdc.2022.09.001Karpouzas GA, Husni ME. Cardiovascular comorbidities in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2023;49(1):XV-XVI. doi: 10.1016/j.rdc.2022.09.001Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759. doi: 10.1016/S0140-6736(19)30417-9Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759. doi: 10.1016/S0140-6736(19)30417-9Weng Q, Chen Q, Jiang T, Zhang Y, Zhang W, Doherty M, et al. Global burden of early-onset osteoarthritis, 1990–2019: Results from the Global Burden of Disease Study 2019. Ann Rheum Dis. 2024:ard-2023-225324. doi: 10.1136/ard-2023-225324Weng Q, Chen Q, Jiang T, Zhang Y, Zhang W, Doherty M, et al. Global burden of early-onset osteoarthritis, 1990–2019: Results from the Global Burden of Disease Study 2019. Ann Rheum Dis. 2024:ard-2023-225324. doi: 10.1136/ard-2023-225324Alexander LAM, Ln D, Eg Z, Is D, Ay K, Ss R, et al. Pharmacological management of osteoarthritis with a focus on symptomatic slow-acting drugs: Recommendations from leading Russian experts. J Clin Rheumatol. 2021;27(8):e533-e539. doi: 10.1097/RHU.0000000000001507Alexander LAM, Ln D, Eg Z, Is D, Ay K, Ss R, et al. Pharmacological management of osteoarthritis with a focus on symptomatic slow-acting drugs: Recommendations from leading Russian experts. J Clin Rheumatol. 2021;27(8):e533-e539. doi: 10.1097/RHU.0000000000001507Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020; 72(2):149-162. doi: 10.1002/acr.24131Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020; 72(2):149-162. doi: 10.1002/acr.24131Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. doi: 10.1016/j.semarthrit.2019.04.008Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. doi: 10.1016/j.semarthrit.2019.04.008Salman LA, Ahmed G, Dakin SG, Kendrick B, Price A. Osteoarthritis: A narrative review of molecular approaches to disease management. Arthritis Res Ther. 2023;25(1):27. doi: 10.1186/s13075-023-03006-wSalman LA, Ahmed G, Dakin SG, Kendrick B, Price A. Osteoarthritis: A narrative review of molecular approaches to disease management. Arthritis Res Ther. 2023;25(1):27. doi: 10.1186/s13075-023-03006-wShumnalieva R, Kotov G, Monov S. Obesity-related knee osteoarthritis – Current concepts. Life (Basel). 2023;13(8):1650. doi: 10.3390/life13081650Shumnalieva R, Kotov G, Monov S. Obesity-related knee osteoarthritis – Current concepts. Life (Basel). 2023;13(8):1650. doi: 10.3390/life13081650Batushansky A, Zhu S, Komaravolu RK, South S, MehtaD’souza P, Griffin TM. Fundamentals of OA. An initiative of osteoarthritis and cartilage. Obesity and metabolic factors in OA. Osteoarthritis Cartilage. 2022;30(4):501-515. doi: 10.1016/j.joca.2021.06.013Batushansky A, Zhu S, Komaravolu RK, South S, MehtaD’souza P, Griffin TM. Fundamentals of OA. An initiative of osteoarthritis and cartilage. Obesity and metabolic factors in OA. Osteoarthritis Cartilage. 2022;30(4):501-515. doi: 10.1016/j.joca.2021.06.013D’Apuzzo MR, Novicoff WM, Browne JA. The John Insall Award: Morbid obesity independently impacts complications, mortality, and resource use after TKA. Clin Orthop Relat Res. 2015;473(1):57- 63. doi: 10.1007/s11999-014-3668-9D’Apuzzo MR, Novicoff WM, Browne JA. The John Insall Award: Morbid obesity independently impacts complications, mortality, and resource use after TKA. Clin Orthop Relat Res. 2015;473(1):57- 63. doi: 10.1007/s11999-014-3668-9Lawrence KW, Sobba W, Rajahraman V, Schwarzkopf R, Rozell JC. Does body mass index influence improvement in patient reported outcomes following total knee arthroplasty? A retrospective analysis of 3918 cases. Knee Surg Relat Res. 2023;35(1):21. doi: 10.1186/s43019-023-00195-1Lawrence KW, Sobba W, Rajahraman V, Schwarzkopf R, Rozell JC. Does body mass index influence improvement in patient reported outcomes following total knee arthroplasty? A retrospective analysis of 3918 cases. Knee Surg Relat Res. 2023;35(1):21. doi: 10.1186/s43019-023-00195-1Chen L, Jia C, Yang H. Causal effect of higher glycated hemoglobin (HbA1c) levels on knee osteoarthritis risk: A Mendelian randomization study. Rheumatol Ther. 2023;10(1):239-247. doi: 10.1007/s40744-022-00510-4Chen L, Jia C, Yang H. Causal effect of higher glycated hemoglobin (HbA1c) levels on knee osteoarthritis risk: A Mendelian randomization study. Rheumatol Ther. 2023;10(1):239-247. doi: 10.1007/s40744-022-00510-4Weijers JM, Müskens WD, van Riel PLCM. Effect of significant weight loss on disease activity: Reason to implement this nonpharmaceutical intervention in daily clinical practice. RMD Open. 2021;7:e001498. doi: 10.1136/rmdopen-2020-001498Weijers JM, Müskens WD, van Riel PLCM. Effect of significant weight loss on disease activity: Reason to implement this nonpharmaceutical intervention in daily clinical practice. RMD Open. 2021;7:e001498. doi: 10.1136/rmdopen-2020-001498Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen AC, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res. 2019;8:F1000 Faculty Rev-2091. doi: 10.12688/f1000research.20575.1Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen AC, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. F1000Res. 2019;8:F1000 Faculty Rev-2091. doi: 10.12688/f1000research.20575.1Katsoula G, Kreitmaier P, Zeggini E. Insights into the molecular landscape of osteoarthritis in human tissues. Curr Opin Rheumatol. 2022;34(1):79-90. doi: 10.1097/BOR.0000000000000853Katsoula G, Kreitmaier P, Zeggini E. Insights into the molecular landscape of osteoarthritis in human tissues. Curr Opin Rheumatol. 2022;34(1):79-90. doi: 10.1097/BOR.0000000000000853Calvet J, García-Manrique M, Berenguer-Llergo A, Orellana C, Cirera SG, Llop M, et al. Metabolic and inflammatory profiles define phenotypes with clinical relevance in female knee osteoarthritis patients with joint effusion. Rheumatology (Oxford). 2023;62(12):3875-3885. doi: 10.1093/rheumatology/kead135Calvet J, García-Manrique M, Berenguer-Llergo A, Orellana C, Cirera SG, Llop M, et al. Metabolic and inflammatory profiles define phenotypes with clinical relevance in female knee osteoarthritis patients with joint effusion. Rheumatology (Oxford). 2023;62(12):3875-3885. doi: 10.1093/rheumatology/kead135Schadler P, Lohberger B, Thauerer B, Faschingbauer M, Kullich W, Stradner MH, et al. The association of blood biomarkers and body mass index in knee osteoarthritis: A cross-sectional study. Cartilage. 2022;13(1):19476035211069251. doi: 10.1177/19476035211069251Schadler P, Lohberger B, Thauerer B, Faschingbauer M, Kullich W, Stradner MH, et al. The association of blood biomarkers and body mass index in knee osteoarthritis: A cross-sectional study. Cartilage. 2022;13(1):19476035211069251. doi: 10.1177/19476035211069251Angelini F, Widera P, Mobasheri A, Blair J, Struglics A, Uebelhoer M, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022;81(5):666-675. doi: 10.1136/annrheumdis-2021-221763Angelini F, Widera P, Mobasheri A, Blair J, Struglics A, Uebelhoer M, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022;81(5):666-675. doi: 10.1136/annrheumdis-2021-221763Nanus DE, Wijesinghe SN, Pearson MJ, Hadjicharalambous MR, Rosser A, Davis ET, Lindsay MA, et al. Regulation of the inflammatory synovial fibroblast phenotype by metastasis-associated lung adenocarcinoma transcript 1 long noncoding RNA in obese patients with osteoarthritis. Arthritis Rheumatol. 2020;72(4):609- 619. doi: 10.1002/art.41158Nanus DE, Wijesinghe SN, Pearson MJ, Hadjicharalambous MR, Rosser A, Davis ET, Lindsay MA, et al. Regulation of the inflammatory synovial fibroblast phenotype by metastasis-associated lung adenocarcinoma transcript 1 long noncoding RNA in obese patients with osteoarthritis. Arthritis Rheumatol. 2020;72(4):609- 619. doi: 10.1002/art.41158Pearson MJ, Herndler-Brandstetter D, Tariq MA, Nicholson TA, Philp AM, Smith HL, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017;7(1):3451. doi: 10.1038/s41598-017-03759-wPearson MJ, Herndler-Brandstetter D, Tariq MA, Nicholson TA, Philp AM, Smith HL, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017;7(1):3451. doi: 10.1038/s41598-017-03759-wWijesinghe SN, Nicholson T, Tsintzas K, Jones SW. Involvements of long noncoding RNAs in obesity-associated inflammatory diseases. Obes Rev. 2021;22(4):e13156. doi: 10.1111/obr.13156Wijesinghe SN, Nicholson T, Tsintzas K, Jones SW. Involvements of long noncoding RNAs in obesity-associated inflammatory diseases. Obes Rev. 2021;22(4):e13156. doi: 10.1111/obr.13156Zhao G, Zhu S, Zhang F, Zhang X, Zhang X, Li T, et al. Global burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990–2019: Findings from the Global Burden of Disease Study 2019. Endocrine. 2023;79(1):60-71. doi: 10.1007/s12020-022-03201-wZhao G, Zhu S, Zhang F, Zhang X, Zhang X, Li T, et al. Global burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990–2019: Findings from the Global Burden of Disease Study 2019. Endocrine. 2023;79(1):60-71. doi: 10.1007/s12020-022-03201-wLiu M, Jin F, Yao X, Zhu Z. Disease burden of osteoarthritis of the knee and hip due to a high body mass index in China and the USA: 1990–2019 findings from the global burden of disease study 2019. BMC Musculoskelet Disord. 2022;23(1):63. doi: 10.1186/s12891-022-05027-zLiu M, Jin F, Yao X, Zhu Z. Disease burden of osteoarthritis of the knee and hip due to a high body mass index in China and the USA: 1990–2019 findings from the global burden of disease study 2019. BMC Musculoskelet Disord. 2022;23(1):63. doi: 10.1186/s12891-022-05027-zMessier SP, Beavers DP, Queen K, Mihalko SL, Miller GD, Losina E, et al. Effect of diet and exercise on knee pain in patients with osteoarthritis and overweight or obesity: A randomized clinical trial. JAMA. 2022;328(22):2242-2251. doi: 10.1001/jama.2022.21893Messier SP, Beavers DP, Queen K, Mihalko SL, Miller GD, Losina E, et al. Effect of diet and exercise on knee pain in patients with osteoarthritis and overweight or obesity: A randomized clinical trial. JAMA. 2022;328(22):2242-2251. doi: 10.1001/jama.2022.21893He M, Lu B, Opoku M, Zhang L, Xie W, Jin H, et al. Metformin prevents or delays the development and progression of osteoarthritis: New insight and mechanism of action. Cells. 2022;11(19):3012. doi: 10.3390/cells11193012He M, Lu B, Opoku M, Zhang L, Xie W, Jin H, et al. Metformin prevents or delays the development and progression of osteoarthritis: New insight and mechanism of action. Cells. 2022;11(19):3012. doi: 10.3390/cells11193012Song Y, Wu Z, Zhao P. The effects of metformin in the treatment of osteoarthritis: Current perspectives. Front Pharmacol. 2022;13: 952560. doi: 10.3389/fphar.2022.952560Song Y, Wu Z, Zhao P. The effects of metformin in the treatment of osteoarthritis: Current perspectives. Front Pharmacol. 2022;13: 952560. doi: 10.3389/fphar.2022.952560Lai FTT, Yip BHK, Hunter DJ, Rabago DP, Mallen CD, Yeoh EK, et al. Metformin use and the risk of total knee replacement among diabetic patients: A propensity-score-matched retrospective cohort study. Sci Rep. 2022;12(1):11571. doi: 10.1038/s41598-022-15871-7Lai FTT, Yip BHK, Hunter DJ, Rabago DP, Mallen CD, Yeoh EK, et al. Metformin use and the risk of total knee replacement among diabetic patients: A propensity-score-matched retrospective cohort study. Sci Rep. 2022;12(1):11571. doi: 10.1038/s41598-022-15871-7Baker MC, Sheth K, Liu Y, Lu D, Lu R, Robinson WH. Development of osteoarthritis in adults with type 2 diabetes treated with metformin vs a sulfonylurea. JAMA Netw Open. 2023;6(3):e233646. doi: 10.1001/jamanetworkopen.2023.3646Baker MC, Sheth K, Liu Y, Lu D, Lu R, Robinson WH. Development of osteoarthritis in adults with type 2 diabetes treated with metformin vs a sulfonylurea. JAMA Netw Open. 2023;6(3):e233646. doi: 10.1001/jamanetworkopen.2023.3646Alimoradi N, Tahami M, Firouzabadi N, Haem E, Ramezani A. Metformin attenuates symptoms of osteoarthritis: Role of genetic diversity of Bcl2 and CXCL16 in OA. Arthritis Res Ther. 2023;25(1):35. doi: 10.1186/s13075-023-03025-7Alimoradi N, Tahami M, Firouzabadi N, Haem E, Ramezani A. Metformin attenuates symptoms of osteoarthritis: Role of genetic diversity of Bcl2 and CXCL16 in OA. Arthritis Res Ther. 2023;25(1):35. doi: 10.1186/s13075-023-03025-7Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. doi: 10.1177/20420188231222367Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. doi: 10.1177/20420188231222367Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36(1):130-143.e5. doi: 10.1016/j.cmet.2023.11.009Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36(1):130-143.e5. doi: 10.1016/j.cmet.2023.11.009Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R, et al. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? J Orthop Translat. 2022;32:121-129. doi: 10.1016/j.jot.2022.02.001Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R, et al. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? J Orthop Translat. 2022;32:121-129. doi: 10.1016/j.jot.2022.02.001Nauck M. Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metabol. 2016;18:203-216. doi: 10.1111/dom.12591Nauck M. Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metabol. 2016;18:203-216. doi: 10.1111/dom.12591Kim S, Jeong J, Jung HS, Kim B, Kim YE, Lim DS, et al. Antiinflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through modulation of IB1/JIP1 expression and JNK signaling in stroke. Exp Neurobiol. 2017;26(4):227-239. doi: 10.5607/en.2017.26.4.227Kim S, Jeong J, Jung HS, Kim B, Kim YE, Lim DS, et al. Antiinflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through modulation of IB1/JIP1 expression and JNK signaling in stroke. Exp Neurobiol. 2017;26(4):227-239. doi: 10.5607/en.2017.26.4.227Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 2013;700:42-50. doi: 10.1016/j.ejphar.2012.12.012Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 2013;700:42-50. doi: 10.1016/j.ejphar.2012.12.012Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab. 2012;97(1):198-207. doi: 10.1210/jc.2011-1508Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab. 2012;97(1):198-207. doi: 10.1210/jc.2011-1508Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J-I. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci Res. 2006;55:352-360. doi: 10.1016/j.neures.2006.04.008Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J-I. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci Res. 2006;55:352-360. doi: 10.1016/j.neures.2006.04.008Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625-635. doi: 10.1038/nrrheum.2010.159Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625-635. doi: 10.1038/nrrheum.2010.159Culemann S, Grüneboom A, Nicolás-Ávila JÁ, Weidner D, Lämmle KF, Rothe T, et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature. 2019;572(7771):670-675. doi: 10.1038/s41586-019-1471-1Culemann S, Grüneboom A, Nicolás-Ávila JÁ, Weidner D, Lämmle KF, Rothe T, et al. Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature. 2019;572(7771):670-675. doi: 10.1038/s41586-019-1471-1Wang N, Liu X, Shi L, Liu Y, Guo S, Liu W, et al. Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects. Biomater Sci. 2020;8(6):1604-1614. doi: 10.1039/c9bm01426hWang N, Liu X, Shi L, Liu Y, Guo S, Liu W, et al. Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects. Biomater Sci. 2020;8(6):1604-1614. doi: 10.1039/c9bm01426hQue Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X, et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J Inflamm (Lond). 2019;16:13. doi: 10.1186/s12950-019-0218-yQue Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X, et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J Inflamm (Lond). 2019;16:13. doi: 10.1186/s12950-019-0218-yBerenbaum F, Meurot C, Breton J, Sudre L, Bougault C, Rattenbach R, et al. THU0055 Anti-degradative and pro-chondrogenic properties of liraglutide, a glucagon-like peptide 1 receptor agonist: Evidence from preclinical studies and implication for osteoarthritis. Ann Rheum Dis. 2020;79:1-239. doi: 10.1136/annrheumdis2020-eular.4606Berenbaum F, Meurot C, Breton J, Sudre L, Bougault C, Rattenbach R, et al. THU0055 Anti-degradative and pro-chondrogenic properties of liraglutide, a glucagon-like peptide 1 receptor agonist: Evidence from preclinical studies and implication for osteoarthritis. Ann Rheum Dis. 2020;79:1-239. doi: 10.1136/annrheumdis2020-eular.4606Chen J, Xie JJ, Shi KS, Gu YT, Wu CC, Xuan J, et al. Glucagonlike peptide-1 receptor regulates endoplasmic reticulum stressinduced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis. 2018;9(2):212. doi: 10.1038/s41419-017-0217-yChen J, Xie JJ, Shi KS, Gu YT, Wu CC, Xuan J, et al. Glucagonlike peptide-1 receptor regulates endoplasmic reticulum stressinduced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis. 2018;9(2):212. doi: 10.1038/s41419-017-0217-yFeng Y, Su L, Zhong X, Guohong W, Xiao H, Li Y, et al. Exendin-4 promotes proliferation and differentiation of MC3T3- E1 osteoblasts by MAPKs activation. J Mol Endocrinol. 2016;56(3):189-199. doi: 10.1530/JME-15-0264Feng Y, Su L, Zhong X, Guohong W, Xiao H, Li Y, et al. Exendin-4 promotes proliferation and differentiation of MC3T3- E1 osteoblasts by MAPKs activation. J Mol Endocrinol. 2016;56(3):189-199. doi: 10.1530/JME-15-0264Berenbaum F, Meurot C, Martin C, Breton J, Jacques C, Favret J, et al. Beneficial structural impact of liraglutide, a GLP1 receptor agonist, in three inflammatory and post-traumatic OA animal models. Arthritis Rheumatol. 2022; 74(Suppl 9). https://acrabstracts.org/abstract/beneficial-structural-impact-of-liraglutidea-glp1-receptor-agonist-in-three-inflammatory-and-post-traumatic-oa-animal-models/.Berenbaum F, Meurot C, Martin C, Breton J, Jacques C, Favret J, et al. Beneficial structural impact of liraglutide, a GLP1 receptor agonist, in three inflammatory and post-traumatic OA animal models. Arthritis Rheumatol. 2022; 74(Suppl 9). https://acrabstracts.org/abstract/beneficial-structural-impact-of-liraglutidea-glp1-receptor-agonist-in-three-inflammatory-and-post-traumatic-oa-animal-models/.Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12. doi: 10.1186/1472-6793-11-12Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12. doi: 10.1186/1472-6793-11-12Pacheco-Pantoja EL, Dillon JP, Wilson PJ, Fraser WD, Gallagher JA. c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines. Purinergic Signal. 2016;12(4):647- 651. doi: 10.1007/s11302-016-9526-3Pacheco-Pantoja EL, Dillon JP, Wilson PJ, Fraser WD, Gallagher JA. c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines. Purinergic Signal. 2016;12(4):647- 651. doi: 10.1007/s11302-016-9526-3Mohsin S, Baniyas MM, AlDarmaki RS, Tekes K, Kalász H, Adeghate EA. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019;19(9):937-948. doi: 10.1080/14712598.2019.1618266Mohsin S, Baniyas MM, AlDarmaki RS, Tekes K, Kalász H, Adeghate EA. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019;19(9):937-948. doi: 10.1080/14712598.2019.1618266Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP1R signaling. J Biol Chem. 2012;287(9):6421-6430. doi: 10.1074/jbc.M111.310342Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP1R signaling. J Biol Chem. 2012;287(9):6421-6430. doi: 10.1074/jbc.M111.310342Sanz C, Vázquez P, Blázquez C, Barrio PA, Alvarez Mdel M, Blázquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab. 2010;298(3):E634-E643. doi: 10.1152/ajpendo.00460.2009Sanz C, Vázquez P, Blázquez C, Barrio PA, Alvarez Mdel M, Blázquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab. 2010;298(3):E634-E643. doi: 10.1152/ajpendo.00460.2009Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab. 2011;13(11):990-1000. doi: 10.1111/j.1463-1326.2011.01431.xJolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab. 2011;13(11):990-1000. doi: 10.1111/j.1463-1326.2011.01431.xGong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci. 2014;34(15):5322- 5334. doi: 10.1523/JNEUROSCI.4703-13.2014Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H, et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci. 2014;34(15):5322- 5334. doi: 10.1523/JNEUROSCI.4703-13.2014Vincent TL. Peripheral pain mechanisms in osteoarthritis. Pain. 2020;161(Suppl 1):S138-S146. doi: 10.1097/j.pain.0000000000001923Vincent TL. Peripheral pain mechanisms in osteoarthritis. Pain. 2020;161(Suppl 1):S138-S146. doi: 10.1097/j.pain.0000000000001923Huang XM, Zhong X, Du YJ, Guo YY, Pan TR. Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients. World J Diabetes. 2023;14(8):1280-1288. doi: 10.4239/wjd.v14.i8.1280Huang XM, Zhong X, Du YJ, Guo YY, Pan TR. Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients. World J Diabetes. 2023;14(8):1280-1288. doi: 10.4239/wjd.v14.i8.1280Gudbergsen H, Overgaard A, Henriksen M, Wæhrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: A randomized controlled trial. Am J Clin Nutr. 2021;113(2):314-323. doi: 10.1093/ajcn/nqaa328Gudbergsen H, Overgaard A, Henriksen M, Wæhrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: A randomized controlled trial. Am J Clin Nutr. 2021;113(2):314-323. doi: 10.1093/ajcn/nqaa328Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, et al. Glucagonlike peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: Findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82(9):1218-1226. doi: 10.1136/ard-2023-223845Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, et al. Glucagonlike peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: Findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82(9):1218-1226. doi: 10.1136/ard-2023-223845Елисеев МС, Паневин ТС, Желябина ОВ, Насонов ЕЛ. Перспективы применения метформина у пациентов с нарушением уратного обмена. Терапевтический архив. 2021;93 (5):628- 634. doi: 10.26442/00403660.2021.05.200795Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. Advantages of the use of metformin in patients with impaired uric acid metabolism. Terapevticheskii arkhiv. 2021;93(5):628-634 (In Russ.)Abdallah MS, Alarfaj SJ, Saif DS, El-Naggar ME, Elsokary MA, Elsawah HK, et al. The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proofof-concept, randomized, double-blind, placebo-controlled trial. Int Immunopharmacol. 2021;95:107575. doi: 10.1016/j.intimp.2021.107575Abdallah MS, Alarfaj SJ, Saif DS, El-Naggar ME, Elsokary MA, Elsawah HK, et al. The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proofof-concept, randomized, double-blind, placebo-controlled trial. Int Immunopharmacol. 2021;95:107575. doi: 10.1016/j.intimp.2021.107575Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, et al. Methotrexate-mediated activation of an AMPKCREB-dependent pathway: A novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75(2):439-448. doi: 10.1136/annrheumdis-2014-206305Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, et al. Methotrexate-mediated activation of an AMPKCREB-dependent pathway: A novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75(2):439-448. doi: 10.1136/annrheumdis-2014-206305Kreiner FF, von Scholten BJ, Kurtzhals P, Gough SCL. Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. Aging Cell. 2023;22(5):e13818. doi: 10.1111/acel.13818Kreiner FF, von Scholten BJ, Kurtzhals P, Gough SCL. Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials. Aging Cell. 2023;22(5):e13818. doi: 10.1111/acel.13818Karacabeyli D, Lacaille D. Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: A scoping review. J Clin Rheumatol. 2024;30(1):26-31. doi: 10.1097/RHU.0000000000001949Karacabeyli D, Lacaille D. Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: A scoping review. J Clin Rheumatol. 2024;30(1):26-31. doi: 10.1097/RHU.0000000000001949Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115(1):56-65. doi: 10.1016/j.ad.2023.06.017Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115(1):56-65. doi: 10.1016/j.ad.2023.06.017Rajagopal S, Alruwaili F, Mavratsas V, Serna MK, Murthy VL, Raji M. Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: From mechanisms of action to clinical applications. Cureus. 2023;15(12):e51352. doi: 10.7759/cureus.51352Rajagopal S, Alruwaili F, Mavratsas V, Serna MK, Murthy VL, Raji M. Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: From mechanisms of action to clinical applications. Cureus. 2023;15(12):e51352. doi: 10.7759/cureus.51352Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019;75:105732. doi: 10.1016/j.intimp.2019.105732Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019;75:105732. doi: 10.1016/j.intimp.2019.105732Tao Y, Ge G, Wang Q, Wang W, Zhang W, Bai J, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life. 2019;71(7):969-977. doi: 10.1002/iub.2031Tao Y, Ge G, Wang Q, Wang W, Zhang W, Bai J, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life. 2019;71(7):969-977. doi: 10.1002/iub.2031Zheng W, Pan H, Wei L, Gao F, Lin X. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol. 2019;74:105649. doi: 10.1016/j.intimp.2019.05.034Zheng W, Pan H, Wei L, Gao F, Lin X. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol. 2019;74:105649. doi: 10.1016/j.intimp.2019.05.034Sullivan C, Gaoatswe G, Gibney J, Healey ML, Doran M, Kane D, et al. Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis. Arthritis Rheum. 2013;65(Suppl 10):S630-S631.Sullivan C, Gaoatswe G, Gibney J, Healey ML, Doran M, Kane D, et al. Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis. Arthritis Rheum. 2013;65(Suppl 10):S630-S631.Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745-2754. doi: 10.1007/s00125-011-2232-3Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745-2754. doi: 10.1007/s00125-011-2232-3Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol. 2019;107:124-128. doi: 10.1016/j.yexmp.2019.01.014Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol. 2019;107:124-128. doi: 10.1016/j.yexmp.2019.01.014Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: A prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: 10.1111/bjd.12886Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Van Belle A, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: A prospective case-series study. Br J Dermatol. 2014;171(1):155-161. doi: 10.1111/bjd.12886Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86-88. doi: 10.1016/j.diabet.2011.11.004Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86-88. doi: 10.1016/j.diabet.2011.11.004Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: 10.1111/j.1468-3083.2012.04609.xAhern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440-1443. doi: 10.1111/j.1468-3083.2012.04609.xXu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019;150:167-173. doi: 10.1016/j.diabres.2019.03.002Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019;150:167-173. doi: 10.1016/j.diabres.2019.03.002Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021;2021:21-0007. doi: 10.1530/EDM-21-0007Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021;2021:21-0007. doi: 10.1530/EDM-21-0007Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: 10.1530/EDM-23-0017Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23-0017. doi: 10.1530/EDM-23-0017Lin L, Xu X, Yu Y, Ye H, He X, Chen S, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392Lin L, Xu X, Yu Y, Ye H, He X, Chen S, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392Chen P, Lin L, Xu X, Zhang Z, Cai W, Shao Z, et al. Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin. J Dermatolog Treat. 2021;32(7):745-751. doi: 10.1080/09546634.2019.1708853Chen P, Lin L, Xu X, Zhang Z, Cai W, Shao Z, et al. Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin. J Dermatolog Treat. 2021;32(7):745-751. doi: 10.1080/09546634.2019.1708853Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766. doi: 10.1016/S0140-6736(21)00184-7Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021; 397(10275):754-766. doi: 10.1016/S0140-6736(21)00184-7Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86. doi: 10.14412/1995-4484-2017-68-86Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30(10):1391-1395. doi: 10.1002/pds.5252Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30(10):1391-1395. doi: 10.1002/pds.5252Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. Ann Intern Med. 2020;172(3):186-194. doi:10.7326/M19-2610Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. Ann Intern Med. 2020;172(3):186-194. doi:10.7326/M19-2610Wood DT, Waterbury NV, Lund BC. Sodium glucose cotransporter 2 inhibitors and gout risk: A sequence symmetry analysis. Clin Rheumatol. 2023;42(9):2469-2475. doi: 10.1007/s10067-023-06647-zWood DT, Waterbury NV, Lund BC. Sodium glucose cotransporter 2 inhibitors and gout risk: A sequence symmetry analysis. Clin Rheumatol. 2023;42(9):2469-2475. doi: 10.1007/s10067-023-06647-zПаневин ТС, Елисеев МС, Шестакова МВ, Насонов ЕЛ. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой. Терапевтический архив. 2020;(5):110-118. doi: 10.26442/00403660.2020.05.000633Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Terapevticheskii arkhiv. 2020;(5):110-118 (In Russ.)Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019;10(4):903- 918. doi: 10.1002/jcsm.12434Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019;10(4):903- 918. doi: 10.1002/jcsm.12434Gurjar AA, Kushwaha S, Chattopadhyay S, Das N, Pal S, China SP, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism. 2020;103:154044. doi: 10.1016/j.metabol.2019.154044Gurjar AA, Kushwaha S, Chattopadhyay S, Das N, Pal S, China SP, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism. 2020;103:154044. doi: 10.1016/j.metabol.2019.154044Kamiya M, Mizoguchi F, Yasuda S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis. J Cachexia Sarcopenia Muscle. 2022;13(4):2118-2131. doi: 10.1002/jcsm.13025Kamiya M, Mizoguchi F, Yasuda S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis. J Cachexia Sarcopenia Muscle. 2022;13(4):2118-2131. doi: 10.1002/jcsm.13025Deng F, Wu W, Fan X, Zhong X, Wang N, Wang Y, et al. Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. Int J Endocrinol. 2023;2023:9926462. doi: 10.1155/2023/9926462Deng F, Wu W, Fan X, Zhong X, Wang N, Wang Y, et al. Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. Int J Endocrinol. 2023;2023:9926462. doi: 10.1155/2023/9926462Kamiya M, Kimura N, Umezawa N, Hasegawa H, Yasuda S. Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy. Front Immunol. 2023;14:1191815. doi: 10.3389/fimmu.2023.1191815Kamiya M, Kimura N, Umezawa N, Hasegawa H, Yasuda S. Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy. Front Immunol. 2023;14:1191815. doi: 10.3389/fimmu.2023.1191815Xu F, Cao H, Chen Z, Gu H, Guo W, Lin B, et al. Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice. Int J Obes (Lond). 2020;44(4):937-947. doi: 10.1038/s41366-019-0513-yXu F, Cao H, Chen Z, Gu H, Guo W, Lin B, et al. Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice. Int J Obes (Lond). 2020;44(4):937-947. doi: 10.1038/s41366-019-0513-yWang L, Guo F, Wei S, Zhao R. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. Peptides. 2011;32(6):1313- 1319. doi: 10.1016/j.peptides.2011.03.018Wang L, Guo F, Wei S, Zhao R. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. Peptides. 2011;32(6):1313- 1319. doi: 10.1016/j.peptides.2011.03.018Khin PP, Hong Y, Yeon M, Lee DH, Lee JH, Jun HS. Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice. Aging (Albany NY). 2021;13(18):21962-21974. doi: 10.18632/aging.203546Khin PP, Hong Y, Yeon M, Lee DH, Lee JH, Jun HS. Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice. Aging (Albany NY). 2021;13(18):21962-21974. doi: 10.18632/aging.203546Yamada S, Ogura Y, Inoue K, Tanabe J, Sugaya T, Ohata K, et al. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2022;539:111472. doi: 10.1016/j.mce.2021.111472Yamada S, Ogura Y, Inoue K, Tanabe J, Sugaya T, Ohata K, et al. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2022;539:111472. doi: 10.1016/j.mce.2021.111472Abdulla H, Phillips BE, Wilkinson DJ, Limb M, Jandova T, Bass JJ, et al. Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell. 2020;19(9):e13202. doi: 10.1111/acel.13202Abdulla H, Phillips BE, Wilkinson DJ, Limb M, Jandova T, Bass JJ, et al. Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell. 2020;19(9):e13202. doi: 10.1111/acel.13202Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M, et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: A pilot study. Medicines (Basel). 2022;9(9):47. doi: 10.3390/medicines9090047Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M, et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: A pilot study. Medicines (Basel). 2022;9(9):47. doi: 10.3390/medicines9090047Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: Efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251-1257. doi: 10.1007/s40520-015-0525-yPerna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: Efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251-1257. doi: 10.1007/s40520-015-0525-ySmits MM, Muskiet MH, Tonneijck L, Kramer MH, Diamant M, van Raalte DH, et al. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol. 2015;35(6):1538-1543. doi: 10.1161/ATVBAHA.115.305447Smits MM, Muskiet MH, Tonneijck L, Kramer MH, Diamant M, van Raalte DH, et al. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol. 2015;35(6):1538-1543. doi: 10.1161/ATVBAHA.115.305447Santo RCDE, Baker JF, Santos LPD, Silva MMMD, Xavier RM. Sarcopenia in immune-mediated rheumatic diseases-review. J Clin Rheumatol. 2023;29(7):354-362. doi: 10.1097/RHU.0000000000001913Santo RCDE, Baker JF, Santos LPD, Silva MMMD, Xavier RM. Sarcopenia in immune-mediated rheumatic diseases-review. J Clin Rheumatol. 2023;29(7):354-362. doi: 10.1097/RHU.0000000000001913Salaffi F, Di Matteo A, Farah S, Di Carlo M. Inflammaging and frailty in immune-mediated rheumatic diseases: How to address and score the issue. Clin Rev Allergy Immunol. 2023;64(2):206-221. doi: 10.1007/s12016-022-08943-zSalaffi F, Di Matteo A, Farah S, Di Carlo M. Inflammaging and frailty in immune-mediated rheumatic diseases: How to address and score the issue. Clin Rev Allergy Immunol. 2023;64(2):206-221. doi: 10.1007/s12016-022-08943-zНасонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi: 10.14412/1995-4484-2017-409-419Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(4):409-419 (In Russ.)Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.)Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. doi: 10.1038/s41569-023-00849-3Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. doi: 10.1038/s41569-023-00849-3Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: Recommendations for clinical practice. Heart. 2022;108(1):73-79. doi: 10.1136/heartjnl-2019-316378Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: Recommendations for clinical practice. Heart. 2022;108(1):73-79. doi: 10.1136/heartjnl-2019-316378Mehta PK, Levit RD, Wood MJ, Aggarwal N, O’Donoghue ML, Lim SS, et al.; American College of Cardiology Cardiovascular Disease in Women Committee. Chronic rheumatologic disorders and cardiovascular disease risk in women. Am Heart J Plus. 2023;27:100267. doi: 10.1016/j.ahjo.2023.100267Mehta PK, Levit RD, Wood MJ, Aggarwal N, O’Donoghue ML, Lim SS, et al.; American College of Cardiology Cardiovascular Disease in Women Committee. Chronic rheumatologic disorders and cardiovascular disease risk in women. Am Heart J Plus. 2023;27:100267. doi: 10.1016/j.ahjo.2023.100267Kwon OC, Han K, Chun J, Kim R, Hong SW, Kim JH, et al.; Gastroenterology, Neurology and Rheumatology National Data Science Research (GUARANTEE) Group. Effects of immunemediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: A nationwide population-based study. Sci Rep. 2022;12(1):11548. doi: 10.1038/s41598-022-15436-8Kwon OC, Han K, Chun J, Kim R, Hong SW, Kim JH, et al.; Gastroenterology, Neurology and Rheumatology National Data Science Research (GUARANTEE) Group. Effects of immunemediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: A nationwide population-based study. Sci Rep. 2022;12(1):11548. doi: 10.1038/s41598-022-15436-8

The authors declare that there are no conflicts of interest present.